Disease/Infection News

RSS

Research looks at potential of pantethine against SARS-CoV-2

In a recent study posted to the Research Square preprint server, researchers assessed the antiviral activity of pantethine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

12 May 2022

Study estimates effectiveness of 2-dose and 3-dose mRNA vaccination against Omicron

In a recent study posted to the medRxiv* preprint server, researchers estimated the efficacy of two-dose and three-dose regimens of two messenger ribonucleic acid (mRNA) vaccines: Moderna’s mRNA-1273 and Pfizer-BioNTech’s BNT162b2 against coronavirus disease 2019 (COVID-19) caused due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant.

12 May 2022

SARS-CoV-2 Omicron escapes immune response due to high ACE2 affinity and low antibody specificity

In a recent study published in the journal Vaccines, researchers revealed how severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron evades neutralizing antibodies (nAbs).

12 May 2022

Antifungal agent Bifonazole as an antiviral against SARS-CoV-2

In a recent study published in the journal Molecular Therapy, researchers identified Bifonazole, an imidazole-based antifungal agent, to have potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using high-throughput screening of small molecules.

12 May 2022

Research describes how DNA damage can affect neural health and function

A new research paper in the journal EMBO Reports describes how DNA damage can affect neural health and function.

12 May 2022

The promise of RNA medicine is targeted and personalized

The development of messenger RNA (mRNA) vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has only increased the impetus in this field.

11 May 2022

Clemson researchers discover a promising therapy for people suffering from toxoplasmosis

Many doctors caution their pregnant patients to avoid cat feces; even the family pet's litter box is off-limits. Now, a group of researchers from Clemson University have discovered a promising therapy for those who suffer from toxoplasmosis, a disease caused by the microscopic protozoa Toxoplasma gondii.

11 May 2022

MRC/UVRI and LSHTM Uganda Research Unit launches new state-of-the-art clinical research facility

The MRC/UVRI and LSHTM Uganda Research Unit has unveiled a new state-of-the-art clinical research facility in Entebbe to further boost its contributions to science, policy and practice in Uganda.

11 May 2022

Discovery of host co-factors necessary for SARS-CoV2 infection

A new study published in the journal EMBO Reports has reported on the shedding of two proteases, namely, ADAM10 and ADAM17, which aids in S protein-dependent molecular events.

11 May 2022

UMSOM researchers participate in Big Ten health registry to learn about cardiac issues in athletes recovering from COVID-19

Researchers at the University of Maryland School of Medicine (UMSOM) have been collaborating on an extensive heart registry that includes student-athletes in the Big Ten athletic conference, to learn more about cardiac issues in those who have recovered from a COVID-19 infection.

11 May 2022

Direct influenza infection of the heart drives cardiac complications, study reveals

Researchers have shown for the first time in mice that heart problems associated with the flu are not caused by raging inflammation in the lungs, as has long been predicted.

11 May 2022

COVID-19 patients with persistent viral shedding may warrant closer surveillance and monitoring for complications

A new Northwestern Medicine study published in GeroScience sought to determine the prevalence, risk factors and significance of persistent viral shedding in hospitalized COVID-19 patients.

11 May 2022

First oral antiviral approved for early treatment of COVID-19

The United States Food and Drug Administration granted an Emergency Use Authorization in December 2021 for the first oral antiviral, a pill containing two protease inhibitors – nirmatrelvir and ritonavir (Paxlovid, Pfizer) – for early treatment of COVID-19.

11 May 2022

Disease/Infection News

Research looks at potential of pantethine against SARS-CoV-2

Study estimates effectiveness of 2-dose and 3-dose mRNA vaccination against Omicron

SARS-CoV-2 Omicron escapes immune response due to high ACE2 affinity and low antibody specificity

Antifungal agent Bifonazole as an antiviral against SARS-CoV-2

Research describes how DNA damage can affect neural health and function

The promise of RNA medicine is targeted and personalized

Clemson researchers discover a promising therapy for people suffering from toxoplasmosis

MRC/UVRI and LSHTM Uganda Research Unit launches new state-of-the-art clinical research facility

Discovery of host co-factors necessary for SARS-CoV2 infection

UMSOM researchers participate in Big Ten health registry to learn about cardiac issues in athletes recovering from COVID-19

Direct influenza infection of the heart drives cardiac complications, study reveals

COVID-19 patients with persistent viral shedding may warrant closer surveillance and monitoring for complications

First oral antiviral approved for early treatment of COVID-19

Unique binding property may explain the ability of delta variant to spread more rapidly

Review portrays clinical journey of messenger RNA vaccines and mRNA-based therapies

Effectiveness of COVID-19 monoclonal antibodies against SARS-CoV-2 Omicron variant

Vaccine features that could induce durable humoral immune responses against SARS-CoV-2

Association between physical activity paradox and risk variables for cardiovascular disease

How is the Antimicrobial Resistance Crisis Impacting Sepsis?

Susceptibility of four SARS-CoV-2 Omicron sub-lineages to vaccines and monoclonal antibodies

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News